Pulmonary vascular disease & thromboembolismRandomised controlled trial
3-Year Outcome in Patients With Combined Precapillary and Postcapillary Pulmonary Hypertension
- Randomised controlled trial
- sham-controlled
Authors' conclusion
PADN is associated with significant improvements in exercise capacity, cardiac function, and clinical outcomes.
Study context
- Population
- Patients with CpcPH (mean PAP ≥25 mm Hg, PCWP >15 mm Hg, PVR >3.0 WU) secondary to left HF
- Participants
- 98 patients
- Comparison
- Pulmonary artery denervation (PADN) vs sham + sildenafil
- Primary endpoint
- Clinical worsening (cardiopulmonary death, rehospitalization or heart/lung transplantation)
- Follow-up
- 3-year follow-up
Primary result
Clinical worsening · 3 years
Hazard ratio
2.13
95% CI 1.19–3.81
P = 0.011
Events by treatment group
Sham + sildenafil vs PADN
HR 2.13 (95% CI 1.19–3.81); P = 0.011
As reported in the abstract
Further findings
| Outcome | PADN | Sham + sildenafil | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| Rehospitalization · 3 years | 35.4% | 56.2% | 1.96 (1.07–3.58) | P = 0.029 | |
| 0.20.5125Hazard ratio (log scale) |
Cardiopulmonary death · end of study
P = 0.167
6-minute walk distance and NT-proBNP
- Greater increase in 6-minute walk distance and reduction in NT-proBNP with PADN
Original publication
3-Year Outcome in Patients With Combined Precapillary and Postcapillary Pulmonary Hypertension. JACC Heart Fail. Published 21 June 2023. doi:10.1016/j.jchf.2023.05.016
Summarised from the published abstract; every number is checked against it